CONNEQT Health has lodged an FDA Pre-Submission for SphygmoCor Cloud, aiming to shift its arterial health analytics from hardware to a scalable software platform with broad commercial potential.
- FDA Pre-Submission lodged for SphygmoCor Cloud SaMD
- Transition from hardware to cloud-based arterial health analytics
- Enables Biomarker-as-a-Service and third-party device integration
- Potential for enterprise licensing and direct-to-consumer applications
- FDA clearance targeted for late 2027, sixth clearance for CONNEQT
FDA Pre-Submission Marks Strategic Shift to Cloud Software
CONNEQT Health (ASX:CQT) has taken a significant regulatory step by lodging a Pre-Submission package with the US Food and Drug Administration for SphygmoCor Cloud, its next-generation Software as a Medical Device (SaMD). This move initiates the pathway to 510(k) clearance, a crucial milestone that could transform the company’s established cardiovascular analytics from dedicated hardware into a cloud-based platform.
Built on five decades of foundational research and over two decades of FDA-cleared clinical use, SphygmoCor technology is globally recognised for non-invasive arterial stiffness and cardiovascular risk assessment. The cloud migration promises to unlock new commercial avenues by enabling integration with third-party devices, enterprise health systems, and consumer digital health applications.
Expanding Market Reach Through Software Licensing
Moving to a cloud-based SaMD platform is not just a technological upgrade, it fundamentally changes CONNEQT’s business model. SphygmoCor Cloud supports a Biomarker-as-a-Service (BaaS) approach, allowing third-party medtech companies and consumer device manufacturers to license CONNEQT's validated arterial health analytics. This opens the door to embedding clinically actionable cardiovascular risk data directly into a wider range of products beyond CONNEQT’s own hardware footprint.
In addition, the platform is designed for enterprise and population health licensing, enabling insurers, health systems, and large employers to deploy cardiovascular risk screening without the need for physical devices. Direct-to-consumer channels, including app-based delivery and telehealth integration, further broaden potential distribution and recurring revenue streams.
Regulatory Timeline and Competitive Edge
The FDA’s formal feedback is expected by August 2026, with a full 510(k) submission targeted for the second quarter of FY27 and clearance anticipated in the latter half of the year. If successful, SphygmoCor Cloud would become CONNEQT’s sixth FDA-cleared product, reinforcing its leadership in clinically validated arterial health biomarkers.
CONNEQT’s competitive advantage rests on a robust clinical evidence base, including thousands of peer-reviewed studies and more than 24 years of FDA-cleared product deployment. This regulatory pathway aligns with a growing trend of AI-enabled and software-based medical devices gaining clearance via 510(k), particularly in cardiology.
Scaling Beyond Device Sales
The transition to software licensing and subscription models complements CONNEQT’s recent commercial momentum, including a A$5.5 million placement to boost growth and a rising revenue run-rate from its Pulse device. SphygmoCor Cloud is positioned as the analytics foundation for all future CONNEQT products, promising a scalable, recurring revenue engine that can operate independently of hardware sales.
CEO Craig Cooper highlighted the strategic significance: "SphygmoCor Cloud adds a second engine to the business, one that can scale independently of hardware and reach a market opportunity substantially larger than our devices alone can access." This cloud platform could enable capital-efficient scaling and strengthen CONNEQT’s global competitive position.
Bottom Line?
CONNEQT’s FDA Pre-Submission for SphygmoCor Cloud signals a pivotal shift towards scalable software solutions, setting the stage for broader market access and recurring revenue, contingent on regulatory clearance.
Questions in the middle?
- How will the market respond to CONNEQT’s shift from hardware to cloud-based analytics?
- What challenges might arise during the FDA clearance process for this SaMD platform?
- Can CONNEQT successfully convert enterprise and consumer markets to its new licensing model?